|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0770 EUR | -3.02% |
|
+4.76% | +18.10% |
| Mar. 09 | TME Pharma Secures 12-month Loan Extension | MT |
| Jan. 05 | TME Pharma N.V. Provides Update on Its Activities | CI |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -58.78 | -82.39 | -100.06 | -90.92 | -111.45 | |||||
Return on Total Capital | -119.74 | -110.03 | -153.93 | -190.72 | -264.38 | |||||
Return On Equity % | -356.13 | -236.93 | -937.03 | 860.28 | -866.97 | |||||
Return on Common Equity | -354.7 | -236.43 | -933.21 | 860.28 | -866.97 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | 100 | - | - | - | |||||
SG&A Margin | 5.37K | 8.72K | - | - | - | |||||
EBITDA Margin % | -16.59K | -40.73K | - | - | - | |||||
EBITA Margin % | -16.64K | -40.79K | - | - | - | |||||
EBIT Margin % | -16.64K | -40.79K | - | - | - | |||||
Income From Continuing Operations Margin % | -29.73K | -43.8K | - | - | - | |||||
Net Income Margin % | -29.73K | -43.79K | - | - | - | |||||
Net Avail. For Common Margin % | -29.73K | -43.79K | - | - | - | |||||
Normalized Net Income Margin | -19.38K | -27.92K | - | - | - | |||||
Levered Free Cash Flow Margin | -11.69K | -22.31K | - | - | - | |||||
Unlevered Free Cash Flow Margin | -11.68K | -22.35K | - | - | - | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.01 | 0 | - | - | - | |||||
Fixed Assets Turnover | 0.27 | 0.36 | - | - | - | |||||
Inventory Turnover (Average Inventory) | - | - | - | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.63 | 1.84 | 0.78 | 0.86 | 1.88 | |||||
Quick Ratio | 3.58 | 1.81 | 0.76 | 0.82 | 1.82 | |||||
Operating Cash Flow to Current Liabilities | -1.8 | -2.35 | -1.88 | -2.02 | -2.59 | |||||
Days Outstanding Inventory (Average Inventory) | - | - | - | - | - | |||||
Average Days Payable Outstanding | - | - | - | - | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.39 | 54.2 | -321.23 | -396.6 | - | |||||
Total Debt / Total Capital | 1.37 | 35.15 | 145.2 | 133.72 | - | |||||
LT Debt/Equity | 0.77 | - | -5.27 | - | - | |||||
Long-Term Debt / Total Capital | 0.76 | - | 2.38 | - | - | |||||
Total Liabilities / Total Assets | 27.75 | 53.91 | 124.27 | 111.8 | 52.61 | |||||
EBIT / Interest Expense | -1.94K | -274.71 | -90.33 | -330.82 | -292.11 | |||||
EBITDA / Interest Expense | -1.92K | -273.37 | -89.64 | -322.35 | -287.78 | |||||
(EBITDA - Capex) / Interest Expense | -1.93K | -273.65 | -89.8 | -323.47 | -288.67 | |||||
Total Debt / EBITDA | -0.02 | -0.18 | -0.34 | -0.21 | - | |||||
Net Debt / EBITDA | 1.77 | 0.52 | 0.05 | 0.2 | 0.63 | |||||
Total Debt / (EBITDA - Capex) | -0.02 | -0.18 | -0.34 | -0.21 | - | |||||
Net Debt / (EBITDA - Capex) | 1.76 | 0.52 | 0.05 | 0.2 | 0.62 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -77.27 | -5.71 | - | - | - | |||||
Gross Profit, 1 Yr. Growth % | -77.27 | -5.71 | - | - | - | |||||
EBITDA, 1 Yr. Growth % | 43.6 | 131.48 | -10.78 | -53.36 | -6.29 | |||||
EBITA, 1 Yr. Growth % | 43.31 | 131.13 | -10.75 | -53.19 | -6.51 | |||||
EBIT, 1 Yr. Growth % | 43.31 | 131.13 | -10.75 | -53.19 | -6.51 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 1.11K | 38.89 | 4.7 | -55.49 | -15.05 | |||||
Net Income, 1 Yr. Growth % | 1.11K | 38.89 | 4.71 | -55.49 | -15.05 | |||||
Normalized Net Income, 1 Yr. Growth % | 1.01K | 35.82 | 4.78 | -54.87 | -17.92 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 316.72 | -31.89 | -41.27 | -89.57 | -88.15 | |||||
Inventory, 1 Yr. Growth % | - | - | - | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -16.9 | -44.07 | 234.85 | -56.56 | -64.58 | |||||
Total Assets, 1 Yr. Growth % | 515.13 | -8.32 | -46.35 | -52.47 | 36.73 | |||||
Tangible Book Value, 1 Yr. Growth % | -517.22 | -41.46 | -128.29 | -76.65 | -640.27 | |||||
Common Equity, 1 Yr. Growth % | -518.34 | -41.44 | -128.17 | -76.89 | -648.98 | |||||
Cash From Operations, 1 Yr. Growth % | 21.89 | 137 | -1.92 | -53.59 | -17.76 | |||||
Capital Expenditures, 1 Yr. Growth % | 143.75 | -64.1 | 50 | -9.52 | -15.79 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -31.78 | 60.34 | -0.16 | -51.39 | -23.52 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -31.79 | 59.16 | 0.14 | -51.73 | -23.69 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | - | -53.71 | - | - | - | |||||
Gross Profit, 2 Yr. CAGR % | - | -53.71 | - | - | - | |||||
EBITDA, 2 Yr. CAGR % | 12.44 | 82.32 | 43.71 | -35.5 | -33.89 | |||||
EBITA, 2 Yr. CAGR % | 12.33 | 82 | 43.63 | -35.36 | -33.84 | |||||
EBIT, 2 Yr. CAGR % | 12.33 | 82 | 43.63 | -35.36 | -33.84 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -1.56 | 309.71 | 20.59 | -31.73 | -38.51 | |||||
Net Income, 2 Yr. CAGR % | -1.54 | 309.7 | 20.59 | -31.73 | -38.51 | |||||
Normalized Net Income, 2 Yr. CAGR % | 2.48 | 288.04 | 19.29 | -31.23 | -39.13 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -65.47 | 68.48 | -36.75 | -75.24 | -88.88 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 89.1 | -31.82 | 36.85 | 20.6 | -60.78 | |||||
Total Assets, 2 Yr. CAGR % | 53.56 | 137.48 | -29.86 | -49.5 | -19.39 | |||||
Tangible Book Value, 2 Yr. CAGR % | 72.13 | 56.28 | -59.31 | -74.3 | 12.33 | |||||
Common Equity, 2 Yr. CAGR % | 72.34 | 56.52 | -59.38 | -74.48 | 12.64 | |||||
Cash From Operations, 2 Yr. CAGR % | 14.28 | 69.96 | 52.46 | -32.54 | -38.22 | |||||
Capital Expenditures, 2 Yr. CAGR % | 108.17 | -6.46 | -26.62 | 16.5 | -12.71 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 32.09 | 10.79 | 26.52 | -30.33 | -39.02 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 30.91 | 10.93 | 26.25 | -30.47 | -39.31 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -46.92 | - | - | - | - | |||||
Gross Profit, 3 Yr. CAGR % | -46.92 | - | - | - | - | |||||
EBITDA, 3 Yr. CAGR % | 7.24 | 43.04 | 43.67 | -1.24 | -26.94 | |||||
EBITA, 3 Yr. CAGR % | 7.19 | 42.87 | 43.52 | -1.16 | -26.9 | |||||
EBIT, 3 Yr. CAGR % | 7.12 | 42.87 | 43.52 | -1.16 | -26.9 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 24.52 | 10.41 | 160 | -13.5 | -26.57 | |||||
Net Income, 3 Yr. CAGR % | 24.55 | 10.42 | 159.99 | -13.49 | -26.57 | |||||
Normalized Net Income, 3 Yr. CAGR % | 23.23 | 12.57 | 150.81 | -13.72 | -27.05 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -49.76 | -56.7 | 18.57 | -65.31 | -80.64 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 35.91 | 25.99 | 15.89 | -6.65 | -19.84 | |||||
Total Assets, 3 Yr. CAGR % | 125.51 | 29.31 | 44.64 | -38.39 | -29.62 | |||||
Tangible Book Value, 3 Yr. CAGR % | 25.3 | 20.15 | -11.6 | -66.18 | -29.07 | |||||
Common Equity, 3 Yr. CAGR % | 25.38 | 20.26 | -11.63 | -66.34 | -29.03 | |||||
Cash From Operations, 3 Yr. CAGR % | 7.23 | 45.74 | 41.5 | 2.56 | -27.93 | |||||
Capital Expenditures, 3 Yr. CAGR % | 169.16 | 15.87 | 9.49 | -21.31 | 4.55 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 6.05 | 46.43 | 7.01 | -8.02 | -28.13 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 19.75 | 45.68 | 7.21 | -8.37 | -28.28 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -4.03 | -41.26 | - | - | - | |||||
Gross Profit, 5 Yr. CAGR % | -26.66 | -36.4 | - | - | - | |||||
EBITDA, 5 Yr. CAGR % | -16.27 | 10.24 | 20.56 | 4.02 | 5.32 | |||||
EBITA, 5 Yr. CAGR % | -16.43 | 9.92 | 20.5 | 4.03 | 5.29 | |||||
EBIT, 5 Yr. CAGR % | -16.47 | 9.84 | 20.45 | 4.03 | 5.29 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -8.36 | 6.09 | 22.93 | -8.9 | 46.05 | |||||
Net Income, 5 Yr. CAGR % | -8.36 | 6.1 | 22.95 | -8.9 | 46.05 | |||||
Normalized Net Income, 5 Yr. CAGR % | -7.02 | 6.98 | 21.64 | -7.57 | 42.35 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -53.49 | -49.56 | -44.91 | -65.38 | -53.99 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -27.84 | -0.3 | 36.29 | 23.81 | -24.87 | |||||
Total Assets, 5 Yr. CAGR % | 12.02 | 27.77 | 41.34 | -11.23 | 14.48 | |||||
Tangible Book Value, 5 Yr. CAGR % | 1.71 | 12.58 | -20.09 | -35.16 | -2.71 | |||||
Common Equity, 5 Yr. CAGR % | 1.86 | 12.73 | -20.12 | -35.31 | -2.62 | |||||
Cash From Operations, 5 Yr. CAGR % | -17.27 | 6.61 | 23.44 | 7.09 | 1.57 | |||||
Capital Expenditures, 5 Yr. CAGR % | 37.28 | -7.79 | 60.04 | 16.12 | 0 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -14.26 | -0.47 | 16.46 | 8.79 | -14.55 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -12.6 | 3.52 | 25.41 | 8.37 | -14.61 |
- Stock Market
- Equities
- ALTME Stock
- Financials TME Pharma N.V.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















